Compound 7 in the series (Figure 9), comprising an ibrutinib-related BTK inhibitor retaining the acrylamide group [97] linked to a VHL-targeting moiety, induced BTK degradation in K562 cells (derived from chronic myelogenous leukemia) with a DC50 of ~150 nM in an 18 h assay. The gene discussed is BTK; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.